Discovers and develops enzymes and other proteins. Offers biocatalyst products and services for various applications. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 2.2× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 51% of them.
Analysts' average target sits 241% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $70.4M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $44.0M against $70.4M in annual sales.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, CDXS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CDXS’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.